Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency - 07/03/18
Abstract |
Background |
Autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency (AD EDA-ID) is caused by heterozygous point mutations at or close to serine 32 and serine 36 or N-terminal truncations in IκBα that impair its phosphorylation and degradation and thus activation of the canonical nuclear factor κ light chain enhancer of activated B cells (NF-κB) pathway. The outcome of hematopoietic stem cell transplantation is poor in patients with AD EDA-ID despite achievement of chimerism. Mice heterozygous for the serine 32I mutation in IκBα have impaired noncanonical NF-κB activity and defective lymphorganogenesis.
Objective |
We sought to establish genotype-phenotype correlation in patients with AD EDA-ID.
Methods |
A disease severity scoring system was devised. Stability of IκBα mutants was examined in transfected cells. Immunologic, biochemical, and gene expression analyses were performed to evaluate canonical and noncanonical NF-κB signaling in skin-derived fibroblasts.
Results |
Disease severity was greater in patients with IκBα point mutations than in those with truncation mutations. IκBα point mutants were expressed at significantly higher levels in transfectants compared with truncation mutants. Canonical NF-κB–dependent IL-6 secretion and upregulation of the NF-κB subunit 2/p100 and RELB proto-oncogene, NF-κB subunit (RelB) components of the noncanonical NF-κB pathway were diminished significantly more in patients with point mutations compared with those with truncations. Noncanonical NF-κB–driven generation of the transcriptionally active p100 cleavage product p52 and upregulation of CCL20, intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 (VCAM1), which are important for lymphorganogenesis, were diminished significantly more in LPS plus α-lymphotoxin β receptor–stimulated fibroblasts from patients with point mutations compared with those with truncations.
Conclusions |
IκBα point mutants accumulate at higher levels compared with truncation mutants and are associated with more severe disease and greater impairment of canonical and noncanonical NF-κB activity in patients with AD EDA-ID.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Ectodermal dysplasia with immune deficiency, NF-κB inhibitor α, canonical nuclear factor κB pathway, noncanonical nuclear factor κB pathway, lymphorganogenesis, hematopoietic stem cell transplantation
Abbreviations used : AD EDA-ID, DN, FKPM, GAPDH, HSCT, IκBα, ICAM-1, IKK, LN, LTo, LTβR, NF-κB, NF-κB1, NF-κB2, NIK, PID, qPCR, RelB, RNA-Seq, S32, S36, SLO, TLR, VCAM-1, WT
Plan
Supported by a scholarship from the DAAD Thematic Network “Research for Rare Diseases and Personalized Medicine” and a Carl Duisberg scholarship from Bayer Foundations (to D.P.) and USPHS grant 1R21AI124101-01 (to R.S.G). |
|
Disclosure of potential conflict of interest: D. Petersheim receives grant support from the DAAD and Bayer Foundations. M. Dorsey receives travel support from CSL Behring and support from the National Institutes of Health (NIH). J.-L. Casanova serves on the board for ADMA; serves as a consultant for Pfizer, Novartis, Sanofi, Genetech, and Neovacs; and receives grant support from Merck Sharpe & Dohme and Biogen Idec. M. H. Albert provides expert testimony for Biotest; receives grant support from GlaxoSmithKline; received payment for lectures from MSD and Jazz; holds stock with Amgen, BMS, Biotest, and Juno; and received travel expenses from Octapharma, Medac, and Neovii. T. R. Torgerson serves as a consultant for Shire Biosciences, UCB Biopharma, CSL Behring, and ADMA Biosciences and receives grant support from Baxalta BioSciences and CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 3
P. 1060 - mars 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?